Cargando…
A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
BACKGROUND: Sunitinib, a tyrosine kinase inhibitor currently in use for the treatment of metastatic renal cell carcinoma (mRCC), has been reported to modulate immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in addition to exerting anti-angiogen...
Autores principales: | Matsushita, Hirokazu, Enomoto, Yutaka, Kume, Haruki, Nakagawa, Tohru, Fukuhara, Hiroshi, Suzuki, Motofumi, Fujimura, Tetsuya, Homma, Yukio, Kakimi, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331924/ https://www.ncbi.nlm.nih.gov/pubmed/25694811 http://dx.doi.org/10.1186/s40425-014-0030-4 |
Ejemplares similares
-
Autologous tumor lysate-loaded dendritic cell vaccination combined with Sunitinib for metastatic renal cell carcinoma
por: Kakimi, Kazuhiro, et al.
Publicado: (2014) -
Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
por: Taguchi, Satoru, et al.
Publicado: (2014) -
Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
por: Sato, Yuzuri Tsurumaki, et al.
Publicado: (2014) -
Multiple primary malignant neoplasms of the glottis, renal pelvis, urinary bladder, oral floor, prostate, and esophagus in a Japanese male patient: a case report
por: Mukaiyama, Yoshihiro, et al.
Publicado: (2014) -
Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
por: Fujimura, Tetsuya, et al.
Publicado: (2015)